Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

daratumumab, dose-attenuated bortezomib, revlimid, and dexamethasone until confirmed disease progression, discontinuation of study treatment due to unacceptable drug toxicity, or other reasons. Throughout the

  • 1 views
  • 16 Feb, 2022
  • 1 location
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

To characterize safety associated with the use of Kyprolis under the locally approved label.

  • 48 views
  • 16 Mar, 2022
  • 18 locations
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (DREAMM 9)

This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide

high dose chemotherapy
measurable disease
chemotherapy regimen
neutrophil count
cell transplantation
  • 14 views
  • 09 Aug, 2022
  • 31 locations
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.

colony stimulating factor
growth factor
bone marrow procedure
ibrutinib
monoclonal antibodies
  • 2 views
  • 28 Jul, 2022
  • 5 locations
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Background B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR). Objective To study …

colony stimulating factor
follicular lymphoma
bone marrow procedure
ibrutinib
obinutuzumab
  • 100 views
  • 23 Jul, 2022
  • 1 location
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Background Aggressive B-cell lymphomas can be cured but people with disease that resists treatment or that returns after treatment have poor outcomes with standard therapies. Indolent B-cell lymphomas are generally incurable with standard therapy and treatment is aimed at controlling symptoms and achieving a durable remissions. Researchers want to see …

colony stimulating factor
bone marrow procedure
ibrutinib
cancer
gm-csf
  • 4 views
  • 24 Jul, 2022
  • 1 location
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) ((COBRA))

This is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly

carfilzomib
bone marrow procedure
serum proteins
revlimid
chemotherapy regimen
  • 71 views
  • 09 Feb, 2022
  • 1 location
DARA RVD For High Risk SMM

The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating

bone marrow procedure
cancer
Accepts healthy volunteers
dexamethasone
lenalidomide
  • 0 views
  • 30 Oct, 2021
  • 2 locations
Daratumumab Carfilzomib Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed Multiple Myeloma

The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab, carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.

carfilzomib
bone marrow procedure
hypercalcemia
corticosteroids
measurable disease
  • 0 views
  • 24 Sep, 2021
  • 1 location
Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment. (CONPET)

A PET-CT will be performed on patients with myeloma after a standard first-line treatment. The PET-positive patients will receive 4 cycles of Carfilzomb-Revlimid-Dexamethason (KRd), before a new

remission
carfilzomib
neutrophil count
platelet count
dexamethasone
  • 2 views
  • 12 Feb, 2022
  • 1 location